Physiological trials with MIF-I in Parkinson's disease (author's transl)

The writers present some physiological (and not therapeutic) acute and sub-acute trials with tripeptide: L-propyl-L-leucyl-glycine amide (M.I.F.-I) in Parkinson's Disease. This work confirms the earlier observation that M.I.F.-I employed alone or in combination with Levodopa is active against Parkinson's disease. The writers evoke the hypothesis that this action takes place at the postsynaptic receptors, whose configuration may be modified in the sense of a hypersensitivity. These studies justify undertaking a series of controlled therapeutic trials when the cost of the product permits and as well instituting development work on analogues active orally.

Medienart:

Artikel

Erscheinungsjahr:

1978

Erschienen:

1978

Enthalten in:

Zur Gesamtaufnahme - volume:134

Enthalten in:

Revue neurologique - 134(1978), 2 vom: 15. Feb., Seite 141-9

Sprache:

Französisch

Weiterer Titel:

Essais physiologiques avec le M.I.F.-I dans la maladie de Parkinson

Beteiligte Personen:

Gonce, M [VerfasserIn]
Barbeau, A [VerfasserIn]

Themen:

9002-79-3
9083-38-9
Antiparkinson Agents
Clinical Trial
English Abstract
Journal Article
MSH Release-Inhibiting Hormone
Melanocyte-Stimulating Hormones

Anmerkungen:

Date Completed 18.11.1978

Date Revised 15.11.2007

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM000303682